Compare STTK & PESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | PESI |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Environmental Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 243.9M |
| IPO Year | 2020 | 1996 |
| Metric | STTK | PESI |
|---|---|---|
| Price | $6.43 | $10.69 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.60 | N/A |
| AVG Volume (30 Days) | ★ 692.3K | 181.4K |
| Earning Date | 03-05-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | 43.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | $642,000.00 |
| Revenue This Year | N/A | $71.17 |
| Revenue Next Year | N/A | $51.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $6.25 |
| 52 Week High | $6.81 | $16.50 |
| Indicator | STTK | PESI |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 32.23 |
| Support Level | $5.75 | $10.06 |
| Resistance Level | N/A | $12.37 |
| Average True Range (ATR) | 0.39 | 0.81 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 72.03 | 24.05 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.